Should I buy or sell Quoin Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QNRX shares. View QNRX analyst ratings or view top-rated stocks .

What is Quoin Pharmaceuticals' stock price target for 2024?

1 brokerages have issued 1 year price targets for Quoin Pharmaceuticals' shares. Their QNRX share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 424.9% from the stock's current price. View analysts price targets for QNRX or view top-rated stocks among Wall Street analysts .

How have QNRX shares performed in 2024?

Quoin Pharmaceuticals' stock was trading at $4.91 on January 1st, 2024. Since then, QNRX shares have decreased by 84.5% and is now trading at $0.7620. View the best growth stocks for 2024 here .

When is Quoin Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our QNRX earnings forecast .

How were Quoin Pharmaceuticals' earnings last quarter?

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) released its quarterly earnings results on Wednesday, March, 13th. The company reported ($2.08) EPS for the quarter, beating the consensus estimate of ($2.37) by $0.29.

When did Quoin Pharmaceuticals' stock split?

Shares of Quoin Pharmaceuticals reverse split before market open on Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Quoin Pharmaceuticals?

Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:QNRX

Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis

→ Does this make you sick? (From Allegiance Gold) (Ad)

Free QNRX Stock Alerts

$0.76

+0.00 (+0.26%)

(As of 01:12 PM ET)

Compare

Today's Range: $0.73
▼
$0.79
50-Day Range: $0.63
▼
$1.19
52-Week Range: $0.60
▼
$12.00

Volume: 30,974 shs
Average Volume: 413,442 shs
Market Capitalization: $3.03 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Quoin Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 424.9% Upside
$4.00 Price Target
Short Interest: Healthy
0.24% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.89 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Quoin Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Quoin Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.
Read more about Quoin Pharmaceuticals' stock forecast and price target.

5.0

Short Interest

Percentage of Shares Shorted
0.24% of the outstanding shares of Quoin Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Quoin Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Quoin Pharmaceuticals has recently decreased by 37.91%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Quoin Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Quoin Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for QNRX.

0.6

News and Social Media Coverage

Search Interest
10 people have searched for QNRX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Quoin Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.30% of the stock of Quoin Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 8.63% of the stock of Quoin Pharmaceuticals is held by institutions.
Read more about Quoin Pharmaceuticals' insider trading history.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Quoin Pharmaceuticals is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Quoin Pharmaceuticals is -0.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Quoin Pharmaceuticals has a P/B Ratio of 0.13. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.
Read more about Quoin Pharmaceuticals' valuation and earnings.

See Top Rated MarketRank™ Stocks Here

Ad Stansberry Research

Warren Buffett's "mystery stock"

WARNING: Read This Before the Next Fed Meeting Investors are looking to the Fed with high hopes for interest rate relief. Unfortunately, many have no idea there's another major story unfolding right now, one that could be worth $40 trillion.

This Wall Street millionaire just stepped forward with all the details, and how it could make some

About Quoin Pharmaceuticals Stock (NASDAQ:QNRX)

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

QNRX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

QNRX Stock News Headlines

May 11, 2024 | americanbankingnews.com

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Short Interest Update

May 9, 2024 | msn.com

Quoin Pharmaceuticals Non-GAAP EPS of -$1.11 misses by $0.70

May 9, 2024 | finance.yahoo.com

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 9, 2024 | globenewswire.com

Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results

May 2, 2024 | globenewswire.com

Quoin Pharmaceuticals to Announce First Quarter 2024 Financial Results on May 9, 2024

March 16, 2024 | seekingalpha.com

Quoin Pharmaceuticals, Ltd. (QNRX) Q4 2023 Earnings Call Transcript

March 15, 2024 | markets.businessinsider.com

Maxim Group Maintains Buy Rating for Quoin Pharmaceuticals: Here's What You Need To Know

March 15, 2024 | finance.yahoo.com

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2023 Earnings Call Transcript

March 14, 2024 | finanznachrichten.de

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

March 14, 2024 | benzinga.com

Quoin Pharmaceuticals: Q4 Earnings Insights

March 13, 2024 | globenewswire.com

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and 2023 Financial Results

March 7, 2024 | msn.com

Why Quoin Pharmaceuticals (QNRX) Shares Are Nosediving

March 7, 2024 | globenewswire.com

Quoin Pharmaceuticals Announces Fourth Quarter and 2023 Financial Results and Corporate Update Conference Call to be held on Thursday March 14th at 8:30 am ET

March 6, 2024 | finance.yahoo.com

QNRX: Potential Pool of Study Participants Expands; Financial Position Strengths

March 5, 2024 | seekingalpha.com

QTI, RNLX and MTC among pre-market losers

March 5, 2024 | msn.com

Why Is Quoin Pharmaceuticals (QNRX) Stock Down 50% Today?

March 5, 2024 | finance.yahoo.com

Quoin Pharmaceuticals Announces Pricing of $6.5 Million Public Offering

March 4, 2024 | marketwatch.com

Quoin Pharma Shares Double After FDA Grants Clearance for Teens in QRX003 Trial

March 4, 2024 | markets.businessinsider.com

Quoin Pharma Says FDA Clears Recruitment Of Teen Subjects For Two Ongoing Clinical Trials For QRX003

March 4, 2024 | msn.com

Why Quoin Pharmaceutical Stock Is Soaring

December 15, 2023 | markets.businessinsider.com

Buy Rating for Quoin Pharmaceuticals Amid Promising Netherton Syndrome Drug Prospects

December 13, 2023 | morningstar.com

Quoin Pharmaceuticals Ltd ADR

December 13, 2023 | finanznachrichten.de

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Announces FDA Clearance of Clinical Optimization Plan for QRX003 for Netherton Syndrome

December 13, 2023 | markets.businessinsider.com

FDA Clears Quoin Pharma's Protocol Amendments For QRX003 Trials In Netherton Syndrome Treatment

November 13, 2023 | finance.yahoo.com

QNRX: Planned Protocol Modifications Might Accelerate QRX003 Regulatory Approval

See More Headlines

Company Calendar

Last Earnings: 3/13/2024
Today: 5/20/2024
Next Earnings (Estimated): 8/07/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:QNRX
CUSIP: N/A
CIK: 1671502
Web: quoinpharma.com
Phone: (703) 980-4182
Fax: 972-9767-8750
Employees: 4
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +426.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($7.27)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-8,690,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -107.57%
Return on Assets: -56.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.61
Quick Ratio: 3.61

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.74 per share
Price / Book: 0.13

Miscellaneous

Outstanding Shares: 3,980,000
Free Float: 3,849,000
Market Cap: $3.02 million
Optionable: Not Optionable
Beta: 1.85

Key Executives

Dr. Michael Myers Ph.D. (Age 62)
Co-Founder, CEO & Chairman
Comp: $661.8k
Ms. Denise Carter (Age 55)
Co-Founder, COO & Director
Comp: $537.8k
Mr. Gordon Bruce Dunn J.D. (Age 60)
Chief Financial Officer
Comp: $523.38k

Key Competitors

View All Competitors

QNRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Quoin Pharmaceuticals stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" QNRX shares.
View QNRX analyst ratings or view top-rated stocks.
What is Quoin Pharmaceuticals' stock price target for 2024?: 1 brokerages have issued 1 year price targets for Quoin Pharmaceuticals' shares. Their QNRX share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 424.9% from the stock's current price.
View analysts price targets for QNRX or view top-rated stocks among Wall Street analysts.
How have QNRX shares performed in 2024?: Quoin Pharmaceuticals' stock was trading at $4.91 on January 1st, 2024. Since then, QNRX shares have decreased by 84.5% and is now trading at $0.7620.
View the best growth stocks for 2024 here.
When is Quoin Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024.
View our QNRX earnings forecast.

How were Quoin Pharmaceuticals' earnings last quarter?: Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) released its quarterly earnings results on Wednesday, March, 13th. The company reported ($2.08) EPS for the quarter, beating the consensus estimate of ($2.37) by $0.29.
When did Quoin Pharmaceuticals' stock split?: Shares of Quoin Pharmaceuticals reverse split before market open on Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
How do I buy shares of Quoin Pharmaceuticals?: Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:QNRX) was last updated on 5/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis

Quoin Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Consensus Rating

Amount of Analyst Coverage

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Dividend Yield

Dividend Growth

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score